СТАТЕВI ОСОБЛИВОСТI ГОМОЦИСТЕЇНЕМIЇ У ХВОРИХ НА ЦУКРОВИЙ ДIАБЕТ 2 ТИПУ В ЗАЛЕЖНОСТI ВIД IНСУЛIНЕМIЇ ТА АНДРОГЕННОГО ЗАБЕЗПЕЧЕННЯ (ОГЛЯД ЛIТЕРАТУРИ ТА ВЛАСНI ДАНI)
DOI:
https://doi.org/10.21856/j-PEP.2010.2.15Ключові слова:
цукровий дiабетАнотація
На сьогоднi чiтко визначено, що цукровий дiабет 2 типу (ЦД-2) є одним iз провiдних чинникiв ризику розвитку iшемiчної хвороби серця (IХС) i iнфаркту мiокарда (IМ). Встановлено, що 80 % всiх випадкiв смертi серед осiб, хворих на дiабет, зумовленi серцево-судинними захворюваннями (ССЗ), а тривалiсть життя при цьому залежить вiд часу їх манiфестацiї. Якщо порiвняти рiвень летальностi вiд ССЗ у загальнiй популяцiї i серед хворих на ЦД-2, то у останнiх вiн у декiлька разiв вищий.
Посилання
Горшунська М.Ю. Мiнорне значення гомоцистеїнемiї в якостi чинника ризику атерогенезу у iнсулiнорезистентних хворих на цукровий дiабет 2 типу за вiдсутностi ниркової недостатностi [Текст] / М.Ю. Горшунська, Ю. Л. Караченцев, Н. С. Красова // Ендокринологiя — 2006 — Т. 11, № 2 — С. 154–163
Кравчун Н. О. Bмicт гомоцистеiну у сироватцi кpoвi хворих на цукровий дiабет 2 типу i його взаемозв’язок iз клiнiко-метаболiчними показниками [Текст] / Н. О. Кравчун // Ендокринологiя — 2006 — Т. 11, № 1 — С. 29–35.
Метаболiзм гомоцистеїну та його роль у патологiї [Текст] / О. О. Пентюк, М. Б. Луцюк, I. I. Андрушко, К. П. Постовiтренко // Укр. бiохiм. журн. — 2003 — Т. 75, № 1 — С. 5–16.
Сергиенко В. И. Математическая статистика в клинических исследованиях [Текст] / В. И. Сергиенко, И. Б. Бондарева — М. : ГЭОТАР-Медиа, 2006 — 303 с.
Уровни гомоцистеина в плазме крови больных с сердечно-сосудистой патологией и сахарным диабетом 2 типа: возможный синергизм факторов риска [Текст] / Н. Д. Халангот, В. К. Гринь, В. О. Высоцкая [и др.] // Ендокринологiя — 2007 — Т. 12, № 2 — С. 262–269.
Шевченко О. П. Гомоцистеин [Текст] / О. П. Шевченко, Г. А. Олефиренко, Н. В. Червякова — М.: 2002 — 47 с.
Plasma homocysteine predicts mortality independently of traditional risk factors and C-Reactive protein in patients with angiographically defined coronary artery disease [Text] / J. L. Anderson, J. B. Muhlestein, B. D. Home [et al.] // Circulation — 2000 — Vol. 102 — P. 1227–1232.
Audelin M. C. Homocysteine and cardiovascular disease in diabetes mellitus [Text] / M. C. Audelin, J. J. Genest // Atherosclerosis — 2001 — Vol. 159 — P. 497–511.
Plasma total homocysteine levels in subjects with hyperinsulinemia [Text] / H. Bar-On, M. Kidron, Y. Friedlander [et al.] // J. Intern. Med. — 2000. — Vol. 247, № 2 — P. 287–294.
The effect of estrogen deficiency, estrogen and estro-progestagene therapy on total plasma homocysteine and serum lipid peroxide levels in postmenopausal women [Text] / G. Bednarek-Tupikowska, K. Tupikowski, B. Bidzińska [et al.] // Ginekol. Pol. — 2005. — Vol. 76, № 9 — P. 687–692.
Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathv, and insulin resistance [Text] / M. Buysschaert, A. S. Dramais, P. E. Wallemacq, M. P. Hermans // Diabetes Care. — 2000. — Vol. 23, № 12 — P. 1816–1822.
Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels [Text] / A. Cagnacci, S. Malmusi, A. L. Zanni [et al.] // Fertil. Steril. — 2004. — Vol. 81 — P. 99–103.
Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease [Text] / S. M. Carlsen, I. Flling, V. Grill [et al.] // Scand. J. Clin. Lab. Invest. — 1997. — Vol. 57, № 6 — P. 521–7.
Plasma Homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? [Text] / A. Chico, A. Perez, A. Cordoba [et al.] // Diabetologia — 1998 — Vol. 41 — P. 684–693.
Endogenous sex steroids and circulating homocysteine in healthy Greek postmenopausal women [Text] / G. E. Christodoulakos, I. V. Lambrinoudaki, D. A. Rizos [et al.] // Hormones — 2006 — Vol. 5, № 1 — P. 35–41.
Plasma testosterone free index: a better indicator of plasma androgen activity? [Text] / A. F. Clark, S. Marcellus, B. de Lory, C. E. Bird // Fertil. Steril. — 1975. — Vol. 26, № 10 — P. 1001–1005.
Dierkes J. Effect of lipid-lowering and antihypertensive drugs on plasma homocysteine levels [Text] / J. Dierkes, C. Luley, S. Westphal // Vase Health. Risk. Manag — 2007 — Vol. 3, № 1 — P. 99–108.
Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence [Text] / J.W. Eikelboom, E. Lonn, J. Jr. Genest [et al.] // Ann. Intern. Med. — 1999. — Vol. 131 — P. 363–375.
Essais O. Factors influencing homocysteineamia in type 2 diabetic patients [Text] / O. Essais, C. Bouzid, Z. Ouni // Tunis. Med. — 2006. — Vol. 84, № 5 — P. 279–281.
Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up [Text] / U. B. Fallon,Y. Ben-Shlomo, P. Elwood [et al.] // Heart. — 2001. — Vol. 85, № 2 — P. 153–158.
Finkelstein J. D. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine [Text] // Clin. Chem. Lab. Med. — 2007. — Vol. 45, № 12 — P. 1694–1699.
Prospective study of coronary heart desease incidence in relation to fasting total homocysteine, related genetic polimorfism and B vitamin [Text] / A. R. Folsom, F. J. Nicto, P. G. Me Govern [et al.] // Circulation. — 1998. — P. 204–210.
Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome? [Text] / J. M. Garcin, S. Cremades, C. Garcia-Hejl [et al.] // Metabol. Syndr. Relat. Disord. — 2006. — Vol. 4, № 3 — P. 185–195.
Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals [Text] / E. J. Giltay, P. Verhoef, L. J. Gooren [et al.] // Atherosclerosis. — 2003. — Vol. 168. — P. 139–146.
Hyperhomocysteinemia and mortality after coronary artery bypass grafting [Text] / D. Girelli, N. Martinelli, O. Olivieri [et al.] // PLoS. ONE. — 2006. — Vol. 1, № 1 — P. 83.
Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status [Text] / M. L. Gravo, L. M. Gloria, J. Selhub [et al.] // Am. J. Clin. Nutr. — 1996. — Vol. 63, № 2 — P. 220–224.
Hyperhomocysteinemia is associated with on increased risk of cardiovascular disease, especially in noninsulin-dependenl
diabetes mellitus. A population-based study [Text] / E. K. Hoogeveen, P. J. Kostense, P. J. Beks [et al.] // Aleroscler. Tromb. Vase. Biol. — 1998. — Vol. 18 — P. 133–138.
Jacobsen D. W. Homocysteine and vitamins in cardiovascular disease [Text] / D.W. Jacobsen // Clin. Chem — 1998. — Vol. 44, № 8 (B). — P. 33–1843.
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study [Text] / E. B. Kilicdag, T. Bagis, H. B. Zeyneloglu [et al.] // Hum. Reprod. — 2005. — Vol. 20, № 4. — P. 894–899.
Lobo R. A. Homocysteine in women’s health [Text] / R. A. Lobo // Menopause. — 2003. — Vol. 10. — P. 271–273.
Manteuffel-Cymborowska M. Tissue-specific effects of testosterone on S-adenosylmethionine formation and utilization in the mouse [Text] / M. ManteuffelCymborowska, W. Chmurzynska, B. Grzelakowska-Sztabert // Biochim. Biophys. Acta. — 1992. — Vol. 1116, № 2. — P. 166–172.
Menopause rather than estrogen modifies plasma homocysteine levels [Text] / D. Marchesoni, L. Driul, L. Plaino [et al.] // Int. J. Gynaecol. Obstet. — 2003. — Vol. 81. — P. 293–297.
Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III [Text] / M. S. Morris, P. F. Jacques, I. H. Rosenberg [et al.] // J. Nutr. — 2000. — Vol. 130. — P. 3073–3076.
Moustapha A. Homocysteine: an emerging agerelated cardiovascularrisk factor [Text] / A. Moustapha, K. Robinson // Geriatrics. — 1999. — Vol. 54. — P. 49–51.
Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease [Text] / M. N. Munshi, A. Stone, L. Fink, V. Fonseca // Metabolism. — 1996. — Vol. 45, № 1 — P. 133–135.
Serum sex hormone and plasma homocysteine levels in middle-aged and elderly men [Text]/ H. R. Nakhai Pour, D. E. Grobbee, M. Muller [et al.] // Europ. J. Endocrinol. — 2006. — Vol. 155, № 6. — P. 887–893.
Plasma homocysteine levels and mortality in patients with coronary artery disease [Text] / O. Nygard, J. E. Nordrehaug, H. Refsum [et al.] // N. Engl. J. Med. — 1997. — Vol. 337. — P. 230–236.
Gonadotropin treatment increases homocysteine levels in idiopathic hypogonadotropic hypogonadism: an indirect effect mediated by changes in body composition [Text] / C. Oktenli, Z. Yesilova, M. Ozata [et al.] // J. Endocrinol. — 2003. — Vol. 179, № 1. — P. 35–39.
Effect of metformin on plasma homocysteine, vitamin B12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus [Text] / M. Pongchaidecha, V. Srikusalanukul, A. Chattananon, S. Tanjariyaporn // J. Med. Assoc. Thai. — 2004. — Vol. 87, № 7. — P. 780–787.
Testosterone regulation of homocysteine metabolism modulates redox status in human prostate cancer cells [Text] / A. Prudova, M. Albin, Z. Bauman [et al.] // Antioxid. Redox. Signal. — 2007. — Vol. 11. — P. 1875–1881.
Evidence for associations between common polymorphisms of estrogen receptor beta gene with homocysteine and nitric oxide [Text] / M. Reimann, K. Vafeiadou, W. L. Hall [et al.] // Climacteric. — 2006. — Vol. 9, № 3. — P. 215–223.
Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus [Text] / M. Sahin, N. B. Tutuncu, D. Ertugrul [et al.] // J. Diabetes. Complications. — 2007. — Vol. 21, № 2. — P. 118–123.
Sbarouni E. The effect of hormone replacement therapy and simvastatin on plasma homocysteine [Text] / E. Sbarouni, Z. S. Kyriakides, D. T. Kremastinos // J. Womens. Health (Larchmt). — 2005. — Vol. 14, № 2. — P. 154–158.
Sheu W. H. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects [Text] / W. H. Sheu, W. J. Lee, Y. T. Chen // Am. J. Hypertens. — 2000. — Vol. 13, № 1. — P. 14–20.
Silberberg J. Gender differences and other determinants of the rise in plasma homocysteine after L-metionine loading [Text] / J. Silberberg // Atherosclerosis. — 1997. — Vol. 133, № 1. — P. 105–110.
Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women [Text] / R. G. Smolders, K. de Meer, P. Kenemans [et al.] // Europ. J. Obstet. Gynecol. Reprod. Biol. — 2004. — Vol. 117, № 1. — P. 55–59.
Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus [Text] / M. Soinio, J. Marniemi, M. Laakso [et al.] // Ann. Intern. Med. — 2004. — Vol. 140, № 2. — P. 94–100.
Effect of age on plasma homocysteine concentrations in young and elderly subjects considering serum vitamin concentrations and different lifestyle factors [Text] / A. Strassburg, C. Krems, P. M. Luhrmann [et al.] // Int. J. Vitam. Nutr. Res. — 2004. — Vol. 74. — P. 129–136.
Changes of plasma total homocysteine levels during the menstrual cycle [Text] / J. Tallova, J. Tomandl, M. Bicikova, M. Hill // Europ. J. Clin. Invest. — 1999. — Vol. 29. — P. 1041–1044.
Temple M. E. Homocysteine as a risk factor for atherosclerosis [Text] / M. E. Temple, A. B. Luzier, D. J. Kazierad // Ann. Pharmacother. — 2000. — Vol. 34, № 1. — P. 57–65.
Folic acid improves endothelial dysfunction in type 2 diabetes–an effect independent of homocysteine-lowering [Text] / L. M. Title, E. Ur, K. Giddens [et al.] // Vasc. Med. — 2006. — Vol. 11, № 2. — P. 101–109.
Homocysteine levels seem to be the main fad or determing familial longevity [Text] / A. Ugalde, M. Fabregate, R. Fabregate [et al.] // Diabetologia. — 2006. — Vol. 49. — P. 713–714.
Vermeulen A. A critical evaluation of simple methods for the estimation of free testosterone in serum [Text] / A. Vermeulen, L. Verdonck, J. M. Kaufman // J. Clin. Endocrinol. Metabol. — 1999. — Vol. 84. — P. 3666–3672.
Testosterone regulation of renal cystathionine betasynthase: implications for sex-dependent differences in plasma homocysteine levels [Text] / V. Vitvitsky, A. Prudova, S. Stabler [et al.] // Am. J. Physiol. Renal. Physiol. — 2007. — Vol. 293, № 2. — P. 594–600.
Homocysteine-induced endoplasmic reticulum stress causes dys-regulation of the cholesterol and triglyceride biosynthetic pathways [Text] / G. H. Werstuck, S. R. Lentz, S. Dayal // J. Clin. Invest. — 2001. — Vol. 107 (10). — P. 1263–1273.
Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial [Text] / M. G. Wulffelé, A. Kooy, P. Lehert [et al.] // J. Intern. Med. — 2003. — Vol. 254, № 5. — P. 455–463.
Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter’s syndrome [Text] / Z. Yesilova, M. Ozata, C. Oktenli [et al.] // Fertil. Steril. — 2004. — Vol. 81, № 5. — P. 1278–1282.
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome [Text] / M. Yilmaz, N. Bukan, G. Ayvaz [et al.] // Hum. Reprod. — 200.5 — Vol. 20, № 12. — P. 3333–3340.
Zhu B. T. Medical hypothesis: hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer [Text] / B. T. Zhu // Int. J. Oncol. — 2003. — Vol. 22, № 3. — P. 499–508.
Zhu B. T. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis [Text] / B. T. Zhu // Histol. Histopathol. — 2002. — Vol. 17, № 4. — P. 1283–1291.
ISSN 
ISSN 
